Lotte Biologics Secures First Large-Scale CMO Contract
Lotte Biologics announced on Nov. 17 that it has signed a biopharmaceutical contract manufacturing organization agreement with a global pharmaceutical company.This contract is the first large-scale commercial production order to be manufactured at Plant 1, which Lotte Biologics constructed at the So
On November 17, Lotte Biologics announced it had secured its first significant contract with a major pharmaceutical corporation. This contract marked the inaugural large-scale commercial production order to be manufactured at Lotte Biologics' Plant 1, which the company built at the Songdo Bio Campus in Incheon. The contract is viewed as a crucial starting point for Lotte Biologics to establish a robust presence in the global contract development and manufacturing organization (CDMO) market.
In line with this, Lotte Biologics intends to offer a comprehensive "One-Stop Service" covering the entire manufacturing spectrum, from generating clinical active pharmaceutical ingredients to producing finished drug products for the client's primary products. The Songdo Plant 1, where the contracted volume will be produced, is a cutting-edge biopharmaceutical manufacturing facility boasting a total capacity of 120,000 liters.
It houses eight 15,000-liter stainless steel bioreactors and is on track to commence full-scale commercial production operations by 2027.
Written by urgent.news from BusinessKorea's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.